Immunomedics (IMMU) Reports New Antibody for Pretargeted Imaging and Therapy of Colorectal Cancer
Tweet Send to a Friend
Immunomedics, Inc. (Nasdaq: IMMU) reported that TF2, a proprietary pretargeting antibody, produced tumor-specific PET imaging and prolonged survival in a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
